Search, analyze & compare
My selected companies
Adjust valuation method
![]()
Detail of Cyteir Therapeutics, Inc.
CEO
Dr. Markus F. Renschler M.D.
Employees
40
Industry
Biotechnology
Sector
Healthcare
Market cap
$108M
Company details
Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. The company is also developing CYT-1853, which is in preclinical trials for solid tumors and hematologic malignancies. The company was incorporated in 2012 and is based in Lexington, Massachusetts.
Stock vs Industry average
-
Industry average
Negative values are hidden from the graph.
Trailing annual dividend rate
$0.00
Payout ratio
0.00%
EPS
-$0.92
Margin profit
0.00%
52 week low
$2.78
52 week high
$3.15
50-day simple moving average
$0.00
200-day simple moving average
$3.02
Percent held by insiders
11.95%
Percent held by institutions
73.65%
Dividend yield
0.00%
